{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:34:01Z","timestamp":1787312041726,"version":"build-2736575974"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Gram-negative bacteria have been one of the most studied classes in the field of microbiology, especially in the context of globally alarming antimicrobial resistance levels to these pathogens over the course of the past decades. With high numbers of these microorganisms being described as multidrug-resistant (MDR), or even extended-drug-resistant (XDR) bacteria, specialists in the field have been struggling to keep up with higher prevalence of difficult-to-treat infections caused by such superbugs. The FDA approval of novel antimicrobials, such as cefiderocol (FDC), ceftolozane\/tazobactam (C\/T), ceftazidime\/avibactam (CZA), imipenem\/relebactam (IMR), sulbactam\/durlobactam (SUL-DUR) and phase 3 clinical trials\u2019 results of aztreonam\/avibactam (ATM-AVI) has proven that, while all these substances provide encouraging efficacy rates, antibiotic resistance keeps up with the pace of drug development. Microorganisms have developed more extensive mechanisms of resistance in order to target the threat posed by these novel antimicrobials, thus equiring researchers to be on a constant lookout for other potential drug candidates and molecule development. However, these strategies require a proper understanding of bacterial resistance mechanisms to gain a comprehensive outlook on the issue. The present review aims to highlight these six antibiotic agents, which have brought hope to clinicians during the past decade, discussing general properties of these substances, as well as mechanisms and patterns of resistance, while also providing a short overview on further directions in the field.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/#searchadvanced<\/jats:ext-link>\n                      , Identifier CRD42024505832.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2024.1385475","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:42:00Z","timestamp":1715301720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Friends or foes? Novel antimicrobials tackling MDR\/XDR Gram-negative bacteria: a systematic review"],"prefix":"10.3389","volume":"15","author":[{"given":"Mihai Octavian","family":"Dan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"T\u01cel\u01cepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s12010-015-1967-6","article-title":"In silico characterization of the binding affinity of dendrimers to penicillin-binding proteins (Pbps): can pbps be potential targets for antibacterial dendrimers?","volume":"178","author":"Ahmed","year":"2016","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: role of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e0040523","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-Tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jiac.2018.10.009","article-title":"The efficacy and safety of tazobactam\/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection","volume":"25","author":"Arakawa","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref5","year":"2024"},{"key":"ref6","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e00528-17","DOI":"10.1128\/mBio.00528-17","article-title":"Klebsiella pneumoniae Carbapenemase-2 (KPC-2), substitutions at ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from \u03b2-lactamase protein engineering","volume":"8","author":"Barnes","year":"2017","journal-title":"mBio"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (credible-cr): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2147\/IDR.S209264","article-title":"Optimal management of complicated infections in the pediatric patient: the role and utility of ceftazidime\/avibactam","volume":"13","author":"Bassetti","year":"2020","journal-title":"Infect Drug Resist."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0048621","DOI":"10.1128\/AAC.00486-21","article-title":"Aztreonam-avibactam susceptibility testing program for metallo-beta-lactamase-producing enterobacterales in the antibiotic resistance laboratory network, March 2019 to December 2020","volume":"65","author":"Bhatnagar","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u2265 3 months to < 18years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime\u2013avibactam in the treatment of children \u2265 3 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/molecules25061340","article-title":"Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime- avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and 40 Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (reprise): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"ofad500.2476","DOI":"10.1093\/ofid\/ofad500.2476","article-title":"2893 a. efficacy and safety of aztreonam-avibactam for the treatment of serious infections due to gram-negative bacteria, including metallo-\u03b2-lactamase-producing pathogens: phase 3 revisit study. Open forum","volume":"10","author":"Carmeli","year":"2023","journal-title":"Infect. Dis."},{"key":"ref16","year":"2024"},{"key":"ref17","year":"2024"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"ofac079","DOI":"10.1093\/ofid\/ofac079","article-title":"A prospective randomized study comparing ceftolozane\/tazobactam to standard of care in the management of neutropenia and fever in patients with hematological malignancies","volume":"9","author":"Chaftari","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jiph.2023.11.003","article-title":"High efficacy and enhanced synergistic activity of the novel siderophore-cephalosporin cefiderocol against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae from inpatients attending a single hospital in the United Arab Emirates","volume":"16","author":"Daoud","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/life13071427","article-title":"An overview of Cefiderocol\u2019s therapeutic potential and underlying resistance mechanisms","volume":"13","author":"Domingues","year":"2023","journal-title":"Life"},{"key":"ref21","year":"2024"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jgar.2022.05.011","article-title":"In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance","volume":"30","author":"Findlay","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/antibiotics11050628","article-title":"Resistance to ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam in gram-negative mdr bacilli: molecular mechanisms and susceptibility testing","volume":"11","author":"Gaibani","year":"2022","journal-title":"Antibiotics"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40265-021-01471-8","article-title":"Imipenem\/cilastatin\/relebactam: a review in gram-negative bacterial infections","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e0044722","DOI":"10.1128\/aac.00447-22","article-title":"Klebsiella pneumoniae Carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview","volume":"66","author":"Hobson","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","article-title":"Antibiotics: past, present and future","volume":"51","author":"Hutchings","year":"2019","journal-title":"Curr. Opin. Microbiol."},{"key":"ref27","year":"2024"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of Cefiderocol, a novel Siderophore cephalosporin, against gram-negative Bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/INF.0000000000003911","article-title":"Safety and efficacy of ceftolozane\/tazobactam plus metronidazole versus meropenem from a phase 2, randomized clinical trial in pediatric participants with complicated intra-abdominal infection","volume":"42","author":"Jackson","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e01801","DOI":"10.1128\/AAC.01801-18","article-title":"ARGONAUT-I: activity of Cefiderocol (S-649266), a Siderophore cephalosporin, against gram-negative Bacteria, including Carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-Spectrum \u03b2-lactamases and Carbapenemases","volume":"63","author":"Jacobs","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1023948","DOI":"10.3389\/fcimb.2023.1023948","article-title":"Optimal treatment of ceftazidime- avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR\/PDR) Pseudomonas aeruginosa","volume":"13","author":"Kang","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e0078122","DOI":"10.1128\/aac.00781-22","article-title":"In vitro activity of Sulbactam-Durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"dlad152","DOI":"10.1093\/jacamr\/dlad152","article-title":"Activity of ceftolozane\/tazobactam, imipenem\/relebactam and ceftazidime\/avibactam against clinical gram-negative isolates-SMART United States 2019-21","volume":"6","author":"Karlowsky","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"dlad149","DOI":"10.1093\/jacamr\/dlad149","article-title":"Susceptibility of gram-negative isolates collected in South Korea to imipenem\/relebactam and comparator agents-SMART 2018-21","volume":"6","author":"Karlowsky","year":"2023","journal-title":"JAC Antimicrob. Resist."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/antibiotics12121729","article-title":"Cefiderocol and sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii","volume":"12","author":"Karruli","year":"2023","journal-title":"Antibiotics"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam\u2013durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (attack)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible gram-negative bacilli, including serine carbapenemase- and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/durlobactam: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jiac.2020.09.032","article-title":"The safety and efficacy of relebactam\/imipenem\/cilastatin in Japanese patients with complicated intra- abdominal infection or complicated urinary tract infection: a multicenter, open-label, noncomparative phase 3 study","volume":"27","author":"Kohno","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (aspect-np): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"31783","DOI":"10.1074\/jbc.M112.348540","article-title":"Exploring the role of a conserved class a residue in the \u03c9-loop of kpc-2 \u03b2-lactamase","volume":"287","author":"Levitt","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1021\/acs.jmedchem.0c02217","article-title":"Total and Semisyntheses of Polymyxin analogues with 2-Thr or 10-Thr modifications to decipher the structure-activity relationship and improve the antibacterial activity","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase ii trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose- ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/ajhp\/zxab012","article-title":"Imipenem\/cilastatin\/relebactam: a new carbapenem \u03b2-lactamase inhibitor combination","volume":"78","author":"Mansour","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1347521","DOI":"10.3389\/fmicb.2024.1347521","article-title":"Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime\/avibactam and ceftolozane\/tazobactam in a tertiary care university hospital center in Portugal - a cross-sectional and retrospective observational study","volume":"15","author":"Mendes Pedro","year":"2024","journal-title":"Front. Microbiol."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"107134","DOI":"10.1016\/j.ijantimicag.2024.107134","article-title":"Intravenous Fosfomycin in combination regimens as a treatment option for difficult-to-treat Infenctions due to multidrug-resistant gram-negative organisms: a real-life experience","volume":"63","author":"Meschiari","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jiac.2018.10.012","article-title":"The efficacy and safety of tazobactam\/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections","volume":"25","author":"Mikamo","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref52","first-page":"479","article-title":"Ceftazidime-avibactam (Avycaz): for the treatment of complicated intra-abdominal and urinary tract infections","volume":"41","author":"Mosley","year":"2016","journal-title":"P T."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"Restore-Imi 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/jac\/dkab346","article-title":"Selection and characterization of mutational resistance to aztreonam\/avibactam in \u03b2-lactamase-producing Enterobacterales","volume":"77","author":"Mushtaq","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e1103","DOI":"10.1093\/cid\/ciaa1799","article-title":"Us food and drug administration (Fda): benefit-risk considerations for cefiderocol (Fetroja\u00ae)","volume":"72","author":"Naseer","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"737288","DOI":"10.3389\/fmicb.2021.737288","article-title":"Function and inhibitory mechanisms of multidrug efflux pumps","volume":"12","author":"Nishino","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e0025622","DOI":"10.1128\/aac.00256-22","article-title":"New perspectives on antimicrobial agents: imipenem-relebactam","volume":"66","author":"O\u2019Donnell","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-023-06799-7","article-title":"A new antibiotic traps lipopolysaccharide in its intermembrane transporter","volume":"625","author":"Pahil","year":"2024","journal-title":"Nature"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/antibiotics11121793","article-title":"Acinetobacter baumannii resistance to sulbactam\/durlobactam: a systematic review","volume":"11","author":"Principe","year":"2022","journal-title":"Antibiotics"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref63","year":"2024"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/INF.0000000000003832","article-title":"Safety and efficacy of ceftolozane\/tazobactam versus meropenem in neonates and children with complicated urinary tract infection, including pyelonephritis: a phase 2, randomized clinical trial","volume":"42","author":"Roilides","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"dlad032","DOI":"10.1093\/jacamr\/dlad032","article-title":"Aztreonam\/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (Cre) collected in hospitals from Europe, Asia and Latin America (2019\u201321)","volume":"5","author":"Sader","year":"2023","journal-title":"JAC Antimicrob. Resist."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"114833","DOI":"10.1016\/j.diagmicrobio.2019.05.005","article-title":"Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018)","volume":"96","author":"Sader","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e01506-19","DOI":"10.1128\/AAC.01506-19","article-title":"Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis","volume":"64","author":"Sagan","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40560-020-0429-6","article-title":"Molecular diversity of extended-spectrum \u03b2-lactamases and carbapenemases, and antimicrobial resistance","volume":"8","author":"Sawa","year":"2020","journal-title":"J. Intensive Care"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/polym13040521","article-title":"Synthesis and antibacterial activity of cationic amino acid-conjugated dendrimers loaded with a mixture of two triterpenoid acids","volume":"13","author":"Schito","year":"2021","journal-title":"Polymers"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40121-023-00771-8","article-title":"\u03b2-Lactam resistance in ESKAPE pathogens mediated through modifications in penicillin-binding proteins: an overview","volume":"12","author":"Sethuvel","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/ijmr.IJMR_2079_17","article-title":"Efflux pump inhibitors for bacterial pathogens: from bench to bedside","volume":"149","author":"Sharma","year":"2019","journal-title":"Indian J. Med. Res."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1128\/JB.00590-16","article-title":"Klebsiella pneumoniae Major Porins OmpK35 and OmpK36 allow more efficient diffusion of \u03b2-lactams than their Escherichia coli homologs OmpF and OmpC","volume":"198","author":"Sugawara","year":"2016","journal-title":"J. Bacteriol."},{"key":"ref75","year":"2024"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","article-title":"A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections","volume":"123","author":"Sun","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"e01026-20","DOI":"10.1128\/mSphere.01026-20","article-title":"Ceftolozane\/tazobactam resistance and mechanisms in carbapenem-nonsusceptible pseudomonas aeruginosa","volume":"6","author":"Teo","year":"2021","journal-title":"mSphere"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e0050023","DOI":"10.1128\/aac.00500-23","article-title":"Successful use of Cefepime-Zidebactam (WCK 5222) as a salvage therapy for the treatment of disseminated extensively drug-resistant New Delhi Metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa infection in an adult patient with acute T-cell leukemia","volume":"67","author":"Tirlangi","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (restore-Imi 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (reprove): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1128\/AAC.01275-10","article-title":"Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence","volume":"55","author":"Tsai","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.jiph.2021.10.020","article-title":"Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects","volume":"14","author":"Uddin","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"100078","DOI":"10.1016\/j.medidd.2020.100078","article-title":"Emerging peptide antibiotics with therapeutic potential","volume":"9","author":"Upert","year":"2021","journal-title":"Med. Drug Discov."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"Van Duin","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime\u2013avibactam versus imipenem\u2013cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/antibiotics12071214","article-title":"Real-life experience of continuously infused Ceftolozane\/Tazobactam in patients with bronchiectasis and multidrug-resistant Pseudomonas aeruginosa infection in the outpatient setting","volume":"12","author":"Venuti","year":"2023","journal-title":"Antibiotics"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: recapture, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime\u2013avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"ofaa651","DOI":"10.1093\/ofid\/ofaa651","article-title":"Meta-analysis of clinical outcomes using ceftazidime\/avibactam, Ceftolozane\/Tazobactam, and Meropenem\/Vaborbactam for the treatment of multidrug-resistant gram-negative infections","volume":"8","author":"Wilson","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10096-023-04645-2","article-title":"In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa\/Middle East, Asia, and Eurasia for the ATLAS global surveillance program in 2019-2021","volume":"42","author":"Wise","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref91","year":"2017"},{"key":"ref92","year":"2021"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (Apeks-np): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"e01726-20","DOI":"10.1128\/AAC.01726-20","article-title":"In vitro activity of Cefepime-Zidebactam, ceftazidime-avibactam, and other comparators against clinical isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: results from China antimicrobial surveillance network (CHINET) in 2018","volume":"65","author":"Yang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3390\/jcm10051068","article-title":"An update on eight \u201cnew\u201d antibiotics against multidrug-resistant gram-negative bacteria","volume":"10","author":"Yusuf","year":"2021","journal-title":"JCM"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v7i2.516","article-title":"Therapeutic bacteriophages for gram-Nega- tive bacterial infections in animals and humans","volume":"7","author":"Zagaliotis","year":"2022","journal-title":"Pathog. Immun."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","article-title":"A novel antibiotic class targeting the lipopolysaccharide transporter","volume":"625","author":"Zampaloni","year":"2024","journal-title":"Nature"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/microorganisms11071690","article-title":"Outer membrane porins contribute to antimicrobial resistance in gram-negative bacteria","volume":"11","author":"Zhou","year":"2023","journal-title":"Microorganisms"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1385475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:42:04Z","timestamp":1715301724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1385475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":98,"alternative-id":["10.3389\/fmicb.2024.1385475"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1385475","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"article-number":"1385475"}}